Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Head-to-Head Comparison: Key Metrics Semaglutide: MW 4113.58 Da | Selective GLP-1 RA | Injectable (weekly) or oral (daily with SNAC) | Mean weight loss 14.9% (STEP 1) | FDA-approved 2021 (obesity) Tirzepatide: MW ~4813.45 Da | Dual GLP-1/GIP | Injectable (weekly) | Mean weight loss 22.5% (SURMOUNT-1) | FDA-approved 2023 (obesity) Retatrutide: MW ~4500 Da | Triple GLP-1/GIP/Glucagon | Injectable (weekly) | Mean weight loss 28.7% (TRIUMPH-4 Phase 3) | Phase 3 as of 2026 Orforglipron: MW 541.65 Da | Selective GLP-1 (non-peptide) | Oral (daily, no food restriction) | Mean weight loss ~14.7% (Phase 3) | FDA-approved April 2026 Receptor Selectivity and Mechanism Differences The four compounds represent a spectrum from single-target to multi-target pharmacology
Lincoff et al
But what about oxidized LDL in the bloodstream
operating with a fleet of roughly 70 tractors, 140 trailers, and employing 85 people
Significant and sustained weight loss : Clinical trials show that adults taking Wegovy lost an average of 15% of their body weight, and adolescents lost ~16% on average when combined with lifestyle changes
It's a big problem, a very big problem, and the ultra-processed foods
US$ 26.01
US$ 27.07
US$ 23.60
US$ 28.52
